These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 16898080

  • 1. Hepatobiliary transport of YM466, a novel factor Xa inhibitor, in rats.
    Mano Y, Usui T, Kamimura H.
    Eur J Drug Metab Pharmacokinet; 2006; 31(2):117-21. PubMed ID: 16898080
    [Abstract] [Full Text] [Related]

  • 2. Primary active transport of pravastatin across the liver canalicular membrane in normal and mutant Eisai hyperbilirubinemic rats.
    Yamazaki M, Kobayashi K, Sugiyama Y.
    Biopharm Drug Dispos; 1996 Oct; 17(7):607-21. PubMed ID: 8894118
    [Abstract] [Full Text] [Related]

  • 3. Absorption, distribution, metabolism and excretion of YM466, a novel factor Xa inhibitor, in rats.
    Mano Y, Sonoda T, Nakamura E, Usui T, Kamimura H.
    Biopharm Drug Dispos; 2004 Sep; 25(6):253-60. PubMed ID: 15334624
    [Abstract] [Full Text] [Related]

  • 4. Biliary excretion of copper, manganese, and horseradish peroxidase in Eisai hyperbilirubinemic mutant rats (EHBRs) with defective biliary excretion of glutathione.
    Sugawara N, Lai Y, Yuasa M, Dhar SK, Arizono K.
    Biol Trace Elem Res; 1996 Sep; 55(1-2):181-9. PubMed ID: 8971365
    [Abstract] [Full Text] [Related]

  • 5. Primary active transport of pravastatin across the liver canalicular membrane in normal and mutant Eisai hyperbilirubinaemic rats.
    Yamazaki M, Kobayashi K, Sugiyama Y.
    Biopharm Drug Dispos; 1996 Nov; 17(8):645-59. PubMed ID: 8950045
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of YM466, a new factor Xa inhibitor, in rats and dogs.
    Mano Y, Usui T, Kamimura H.
    Eur J Drug Metab Pharmacokinet; 2004 Nov; 29(1):7-13. PubMed ID: 15151165
    [Abstract] [Full Text] [Related]

  • 7. Key determinants of the circulatory exposure of organic anions: differences in hepatic uptake between multidrug resistance-associated protein 2 (Mrp2)-deficient rats and wild-type rats.
    Kosaka K, Watanabe T, Susukida T, Aoki S, Sekine S, Kume T, Ito K.
    Xenobiotica; 2015 Nov; 45(6):556-62. PubMed ID: 25539456
    [Abstract] [Full Text] [Related]

  • 8. Involvement of multidrug resistance-associated protein 2 (ABCC2/Mrp2) in biliary excretion of micafungin in rats.
    Abe F, Ueyama J, Kimata A, Kato M, Hayashi T, Nadai M, Saito H, Takeyama N, Noguchi H, Hasegawa T.
    Life Sci; 2008 Aug 15; 83(7-8):229-35. PubMed ID: 18638490
    [Abstract] [Full Text] [Related]

  • 9. Aminoalkylmethacrylate copolymer E improves oral bioavailability of YM466 by suppressing drug-bile interaction.
    Takemura S, Kondo H, Watanabe S, Sako K, Ogawara K, Higaki K.
    J Pharm Sci; 2013 Sep 15; 102(9):3128-35. PubMed ID: 23459999
    [Abstract] [Full Text] [Related]

  • 10. Mechanism of hepatobiliary transport of a novel thromboxane A2 receptor antagonist, [2-(4-chlorophenylsulfonylaminomethyl)indan-5-yl]acetate (Z-335), and its xenobiotic taurine conjugate (Z-335-Tau) in rats.
    Kawabata Y, Nakamura H, Kamada E, Furuta S, Shinozaki Y, Kurimoto T, Nishigaki R.
    J Pharm Sci; 2003 Jan 15; 92(1):67-76. PubMed ID: 12486683
    [Abstract] [Full Text] [Related]

  • 11. Involvement of multidrug resistance-associated protein 2 (Abcc2) in molecular weight-dependent biliary excretion of beta-lactam antibiotics.
    Kato Y, Takahara S, Kato S, Kubo Y, Sai Y, Tamai I, Yabuuchi H, Tsuji A.
    Drug Metab Dispos; 2008 Jun 15; 36(6):1088-96. PubMed ID: 18339814
    [Abstract] [Full Text] [Related]

  • 12. Positron emission tomography studies using (15R)-16-m-[11C]tolyl-17,18,19,20-tetranorisocarbacyclin methyl ester for the evaluation of hepatobiliary transport.
    Takashima T, Nagata H, Nakae T, Cui Y, Wada Y, Kitamura S, Doi H, Suzuki M, Maeda K, Kusuhara H, Sugiyama Y, Watanabe Y.
    J Pharmacol Exp Ther; 2010 Nov 15; 335(2):314-23. PubMed ID: 20716623
    [Abstract] [Full Text] [Related]

  • 13. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans.
    Yamashiro W, Maeda K, Hirouchi M, Adachi Y, Hu Z, Sugiyama Y.
    Drug Metab Dispos; 2006 Jul 15; 34(7):1247-54. PubMed ID: 16624871
    [Abstract] [Full Text] [Related]

  • 14. Drug interaction between sunitinib and cimetidine and contribution of the efflux transporter ATP-binding cassette C2 to biliary excretion of sunitinib in rats.
    Arakawa-Todo M, Ueyama J, Nomura H, Abe F, Tsukiyama I, Matsuura K, Hasegawa T.
    Anticancer Res; 2013 Aug 15; 33(8):3105-11. PubMed ID: 23898066
    [Abstract] [Full Text] [Related]

  • 15. Involvement of sulfate conjugation and multidrug resistance-associated protein 2 (Mrp2) in sex-related differences in the pharmacokinetics of garenoxacin in rats.
    Hayashi T, Abe F, Kato M, Saito H, Ueyama J, Kondo Y, Imai K, Katoh M, Nadai M, Hasegawa T.
    J Infect Chemother; 2011 Feb 15; 17(1):24-9. PubMed ID: 20676911
    [Abstract] [Full Text] [Related]

  • 16. Mrp2 is involved in benzylpenicillin-induced choleresis.
    Ito K, Koresawa T, Nakano K, Horie T.
    Am J Physiol Gastrointest Liver Physiol; 2004 Jul 15; 287(1):G42-9. PubMed ID: 15194559
    [Abstract] [Full Text] [Related]

  • 17. Treatment of hyperbilirubinemia in Eisai hyperbilirubinemic rat by transfecting human MRP2/ABCC2 gene.
    Hirouchi M, Suzuki H, Sugiyama Y.
    Pharm Res; 2005 Apr 15; 22(4):661-6. PubMed ID: 15846474
    [Abstract] [Full Text] [Related]

  • 18. Lack of Contribution of Multidrug Resistance-associated Protein and Organic Anion-transporting Polypeptide to Pharmacokinetics of Regorafenib, a Novel Multi-Kinase Inhibitor, in Rats.
    Hotta K, Ueyama J, Tatsumi Y, Tsukiyama I, Sugiura Y, Saito H, Matsuura K, Hasegawa T.
    Anticancer Res; 2015 Sep 15; 35(9):4681-9. PubMed ID: 26254357
    [Abstract] [Full Text] [Related]

  • 19. Alterations in the pharmacokinetics and protein binding of enprofylline in Eisai hyperbilirubinemic rats.
    Nadai M, Hasegawa T, Wang L, Tagaya O, Nabeshima T.
    Drug Metab Dispos; 1994 Sep 15; 22(4):561-5. PubMed ID: 7956730
    [Abstract] [Full Text] [Related]

  • 20. Ticlopidine, a cholestatic liver injury-inducible drug, causes dysfunction of bile formation via diminished biliary secretion of phospholipids: involvement of biliary-excreted glutathione-conjugated ticlopidine metabolites.
    Yoshikado T, Takada T, Yamamoto H, Tan JK, Ito K, Santa T, Suzuki H.
    Mol Pharmacol; 2013 Feb 15; 83(2):552-62. PubMed ID: 23220748
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.